awmsg logo



fondaparinux (Arixtra®)


Reference No. 148

Publication date:
22/05/2008


Appraisal information

fondaparinux (Arixtra®) solution for injection


Company: GlaxoSmithKline
BNF category: Cardiovascular system
NMG meeting date: 13/03/2008
AWMSG meeting date: 16/04/2008
   
   
Submission Type: Full Submission
Status: Recommended
Advice No: 0608
Ministerial ratification: 20/05/2008

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Fondaparinux (Arixtra®) should be recommended as an option for use in the treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients for whom urgent (less than 120 minutes) invasive management (percutaneous coronary intervention [PCI]) is not indicated. Treatment with fondaparinux (Arixtra®) and its monitoring/supervision should be retained under secondary care. AWMSG is of the opinion that fondaparinux (Arixtra®) would not be suitable for shared care within NHS Wales.
Final Appraisal Recommendation (FAR)
Download